Dhootapapeshwar Shoolavajrini Vati (60tab) : Indicated in Abdominal pain, digestive impairment, indigestion, vomiting.
About Dhootapapeshwar Shoolwarjini (Vajrini) Vati
Batch to batch performance and complete purity and safety are assured through the application of advanced pharmaceutical technology at every stage of manufacture. Dhooptapeshwar was founded in the pre-independence state of Maharastra and has made a name for itself as a unique product in the ayurveda market. ISO 9001: 2000 certification was given for the design, manufacture, and marketing of herbal health care products.
Abdominal pain, abdominal gas, and all types of colic can be effectively treated with the help of the herbal and mineral Ayurvedic medicine known as shoolwarjini bati.
Shoolwarjini bati strengthens the digestive system and aids in toxin removal from the body.
Ingredients of Dhootapapeshwar Shoolwarjini (Vajrini) Vati
Kajjali
Bhasma Lauh
Hing
Tankan
Trikatu
Trifhala
Jaiphal
Bhasma Shankha
Indications of Dhootapapeshwar Shoolwarjini (Vajrini) Vati
stomach ache
Gulma
the spleen growing larger
abdominal gas that is too much
Colic of all kinds
Dosage of Dhootapapeshwar Shoolwarjini (Vajrini) Vati
Once or twice a day, one to two tabs with water.
Precautions of Dhootapapeshwar Shoolwarjini (Vajrini) Vati
1. Keep kids out of your sight and out of your reach.
2. Due to its potency, it should be used with caution by those who have Pitta roga, hyperacidity, bleeding disorders, or ulcers.
3. It acts as an emmenagogue; use during pregnancy is not advised.
5. It contains jaggery, making it unsuitable for diabetics, and should only be taken in the recommended doses because high doses vitiate all doshas and cause burning sensations.
- Self-medication is not advised.
Terms and Conditions
Before purchasing this medication, we have assumed that you sought medical advice and are not using it for self-medication.
Attributes | |
---|---|
Brand | Dhootapapeshwar |
Remedy Type | Ayurvedic |
Country of Origin | India |
Form Factor | Tablet |
Price | ₹ 135 |
Comments are closed.